News & Media

Press release
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024

In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 7 May 2024...

Read more
Press release
Medivir to present at Redeye Growth Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release Regulatory
Resolutions at the Annual General Meeting in Medivir on 7 May 2024

Medivir Aktiebolag (publ) held its annual general meeting today on 7 May 2024. The annual general meeting was held by physical...

Read more
Press release Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2024

”Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened...

Read more
Press release
Medivir brings the Q1 webcast forward to 10 a.m. on April 30

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
Medivir to present at Investing in Oncology Forum on April 10

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more